


## NH2-PEG8-acid

Cat. No.:	HY-W019798
CAS No.:	756526-04-2
Molecular Formula:	C <sub>19</sub> H <sub>39</sub> NO <sub>10</sub>
Molecular Weight:	441.51
Target:	ADC Linker; PROTAC Linkers
Pathway:	Antibody-drug Conjugate/ADC Related; PROTAC
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (113.25 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div><div>Mass</div></div>	1 mg	5 mg	10 mg
		1 mM	2.2650 mL	11.3248 mL	22.6495 mL
		5 mM	0.4530 mL	2.2650 mL	4.5299 mL
		10 mM	0.2265 mL	1.1325 mL	2.2650 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.66 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	NH2-PEG8-acid is a non-cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) <sup>[1]</sup> . NH2-PEG8-acid also is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[2]</sup> .	
IC <sub>50</sub> & Target	Non-cleavable Linker	PEGs
In Vitro	<p>ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker<sup>[1]</sup>. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	

---

## REFERENCES

- [1]. Michael Nathaniel ALONSO, et al. Antibody adjuvant conjugates. WO2018009916A1.
- [2]. "An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562."
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA